Advances in Type 1 Diabetes Therapeutics: Immunomodulation and β-Cell Salvage

Endocrinology and Metabolism Clinics of North America

Volumn 38, Issue 2, 2009, Pages 303-317

  Waldron Lynch, Frank ^a   Herold, Kevan C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cell; Autoimmunity; Immune therapy; Type 1 diabetes

Indexed keywords

DIAPEP277 PEPTIDE; GLUTAMATE DECARBOXYLASE 65; INSULIN; MONOCLONAL ANTIBODY CD3; NICOTINAMIDE; PEPTIDE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG;

B LYMPHOCYTE; HEALTH CARE COST; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; UNITED STATES;

ANIMALS; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; INSULIN-SECRETING CELLS;

ANIMALIA;

EID: 62749168302     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2009.01.005     Document Type: Review

References (110)

1. La Porte R.E., Matsushima M., and Chang Y.F. Prevalence and incidence of insulin-dependant diabetes. 2nd Edition (1995), National Institutes of Health, NIH publ, Bethesda No. 95-1468
2. Onkamo P., Vaananen S., Karvonen M., et al. World wide increase in the incidence of Type 1 diabetes-analysis of the data on published incidence trends. Diabetologia 42 (1999) 1395-1403
3. Dahlquist G., and Mustonen L. Analysis of 20 years of prospective registration of childhood onset diabetes time trends and birth cohort effects. Swedish Childhood Study Group. Acta Paediatr 89 (2000) 1231-1237
4. Weet I., De Leeuw I.H., Du Caju M.V., et al. The incidence of type 1 diabetes in the age group 0-39 years has not increased in Antwerp (Belgium) between 1989 and 2000. Diabetes Care 25 (2002) 840-846
5. World Health Organization. Available at: (Accessed December 1, 2008). http://www.who.int/en
6. Atkinson M.A. ADA Outstanding Scientific Achievement Lecture 2004. Thirty years of investigating the autoimmune basis for type 1 diabetes: why can't we prevent or reverse this disease?. Diabetes 54 (2005) 1253-1263
7. Steele C., Hagopian W.A., Gitelman S., et al. Insulin secretion in type 1 diabetes. Diabetes 53 2 (2004) 426-433
8. Delovitch T.L., and Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 7 6 (1997) 727-738
9. Wen L., Chen N.Y., Tang J., et al. The regulatory role of DR4 in a spontaneous diabetes DQ8 transgenic model. J Clin Invest 107 7 (2001) 871-880
10. Roy C.J., Warfield K.L., Welcher B.C., et al. Human leukocyte antigen-DQ8 transgenic mice: a model to examine the toxicity of aerosolized staphylococcal enterotoxin B. Infect Immun 73 4 (2005) 2452-2460
11. Wicker L.S., Leiter E.H., Todd J.A., et al. Beta 2-microglobulin-deficient NOD mice do not develop insulitis or diabetes. Diabetes 43 3 (1994) 500-504
12. Serreze D.V., and Silveira P.A. The role of B lymphocytes as key antigen-presenting cells in the development of T cell-mediated autoimmune type 1 diabetes. Curr Dir Autoimmun 6 (2003) 212-227
13. Foulis A.K., McGill M., and Farquharson M.A. Insulitis in type 1 (insulin-dependent) diabetes mellitus in man-macrophages, lymphocytes, and interferon-gamma containing cells. J Pathol 165 2 (1991) 97-103
14. Itoh N., Hanafusa T., Miyazaki A., et al. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest 92 (1993) 2313-2322
15. Dotta F., Censini S., van Halteren A.G., et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A 104 12 (2007) 5115-5120
16. Wang W.Y., Barratt B.J., Clayton D.G., et al. Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet 6 2 (2005) 109-118
17. Todd J.A., Walker N.M., Cooper J.D., et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 39 7 (2007) 857-864
18. Kent S.C., Chen Y., Bregoli L., et al. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize the insulin epitope. Nature 435 (2005) 224-228
19. Mannering S.I., Harrison L.C., Williamson N.A., et al. The insulin A-chain epitope recognized by human T cells is post translationally modified. J Exp Med 202 (2005) 1191-1197
20. Nakayama M., Abiru N., Moriyama H., et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435 7039 (2005) 220-223
21. Jahromi M.M., and Eisenbarth G.S. Cellular and molecular pathogenesis of type 1A diabetes. Cell Mol Life Sci 64 (2007) 865-872
22. Krishnamurthy B., Mariana L., Gellert S.A., et al. Autoimmunity to both proinsulin and IGRP is required for diabetes in nonobese diabetic 8.3 TCR transgenic mice. J Immunol 180 7 (2008) 4458-4464
23. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 31 (2008) S12-S54
24. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
25. Perkin B.A., Ficocrello L.H., Silva K.H., et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 348 (2003) 2085-2093
26. Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 46 2 (1997) 271-286
27. Purnell J.Q., Hokanson J.E., Marcovina S.M., et al. Effect of excessive weight gain with insulin therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. The Diabetes Control and Complications Trial. JAMA 280 (1998) 140-146
28. Boland E., Monsod T., Delucia M., et al. Limitations of conventional methods of self monitoring of blood glucose: lessons learned from three days of continuous glucose sensing in paediatric patients with type 1 diabetes. Diabetes Care 24 11 (2001) 1858-1862
29. Liu E., and Eisenbarth G.S. Type IA diabetes mellitus-associated autoimmunity. Endocrinol Metab Clin North Am 31 (2002) 391-410 vii-viii
30. Waldron-Lynch F., von Herrath M., and Herold K.C. Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of β cell mass. 2007 Defining Optimal Immunotherapies for Type 1 Diabetes. Novartis Found Symp 292 (2009) 146-155
31. Fousteri G., Bresson, and von Herrath M. Rational development of antigen-specific therapies for type 1 diabetes. Adv Exp Med Biol 601 (2007) 313-319
32. Cobbold S.P., Nolan K.F., Graca L., et al. Regulatory T cells and dendritic cells in transplantation tolerance: molecular markers and mechanisms. Immunol Rev 196 (2003) 109-124
33. St. Clair E.M., Turka L.A., Saxon A., et al. New reagents on the horizon for immune tolerance. Annu Rev Med 58 (2007) 329-346
34. Graca L., Chen T.C., Le Moine A., et al. Dominant tolerance: activation thresholds for peripheral generation of regulatory T cells. Trends Immunol 26 (2005) 131-135
35. Haller M.J., Gottieb P.A., and Schatz D.A. Type 1 diabetes intervention trials 2007: where are we and where are we going?. Curr Opin Endocrinol Diabetes Obes 14 (2007) 283-287
36. Roep B.O. Are insights gained from NOD mice sufficient to guide clinical translation?. Ann N Y Acad Sci 1103 (2007) 1-10
37. Keller R.J., Eisenbarth G.S., and Jackson R.A. Insulin prophylaxis in individuals at high risk of type 1 diabetes. Lancet 341 (1993) 927-928
38. Fuchtenbusch M., Rabl W., Grassi B., et al. Delay of type 1 diabetes in high risk, first degree relatives by parental antigen administration: the Schwabling Insulin Prophylaxis Pilot Trial. Diabetologia 41 (1998) 536-541
39. Skyler J.S., Krischer J.P., Wolfsorf J., et al. Effects of oral insulin in relatives of patients with type 1 diabetes. Diabetes Prevention Trial-Type 1. Diabetes Care 28 (2005) 1068-1076
40. Available at:. http://www.diabetestrialnet.org Accessed December 1, 2008
41. Harrison L.C., Honeyman M.C., Steele C.E., et al. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 27 10 (2004) 2348-2355
42. Available at:. http://www.thegeorgeinstitute.org Accessed December 1, 2008
43. Horvath L., Cervenak L., Orosazlan M., et al. Antibiodies against different epitopes of heat shock protein 60 in children with type 1 diabetes mellitus. Immunol Lett 80 3 (2002) 155-162
44. Brudzynski K., Martinez V., and Gupta R.S. Secretory granule autoantigen in insulin-dependent diabetes mellitus is related to 62 kDa heat-shock protein (hsp60). J Autoimmun 5 4 (1992) 453-463
45. Cohen I.R. Peptide therapy for type 1 diabetes: the immunological homunculus and the rational for vaccination. Diabetologia 45 (2002) 1468-1474
46. Brugman S., Klatter F.A., Visser J., et al. Neonatal administration of DiaPep277 combined with hydrolysed casein diet, protects against Type 1 diabetes in BB-DP rat. An experimental study. Diabetologia 47 7 (2004) 1331-1333
47. Zanin-Zhorov A., Bruck R., Tal G., et al. Heat shock protein 60 inhibits Th1-mediated hepatitis model via innate regulation of Th1/Th2 transcription factors and cytokines. J Immunol 174 6 (2005) 3227-3236
48. Nussbaum G., Zanin-Zhorov A., Quintana F., et al. Peptide p277 of HSP60 signals T cells: inhibition of inflammatory chemotaxis. Int Immunol 18 (2006) 1413-1419
49. Raz I., Elias D., Avron A., et al. Beta cell function in new-onset type 1 diabetes and immunomodulation with heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 358 (2001) 1749-1753
50. Elias D., Raz I., Avron A., et al. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomised, double-blind, phase II trial. Diabetes Metab Res Rev 23 (2007) 292-298
51. Roep B., Huurman V., Decochez K., et al. Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev 23 (2007) 269-275
52. Schloot N., Meierhoff G., Lengyel C., et al. Effect of heat shock protein peptide DiaPep277 on β-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomised, double blind phase II trials. Diabetes Metab Res Rev 23 (2007) 276-285
53. Lazar L., Ofan R., Weintrob N., et al. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabetes Metab Res Rev 23 (2007) 286-291
54. Baekkeskov S., Aanstoot H.J., Christgau S., et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 347 (1990) 151-156
55. Oling V., Marttila J., Ilonen J., et al. GAD65 and proinsulin-specific CD4 + T cells detected by MHC class II tetramers in peripheral blood of type 1 diabetes patients and at-risk subjects. J Autoimmun 25 (2005) 235-243
56. Tian J., Atkinson M.A., Clare-Salzler M., et al. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 183 (1996) 1561-1567
57. Tian J., Clare-Salzler M., Herschenfeld A., et al. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med 2 12 (1996) 1348-1353
58. Agardh C.D., Cilio C.M., Lethagen A., et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabet Complications 19 (2005) 238-246
59. Available at:. http://www.diamyd.com Accessed December 1, 2008
60. Yamada K., Nonaka K., Hanafusa T., et al. Preventive and therapeutic effects of large-dose nicotinamide injections on diabetes associated with insulitis. An observation in nonobese diabetic (NOD) mice. Diabetes 31 9 (1982) 749-753
61. Reddy S., Bibby N.J., and Elliott R.B. Early nicotinamide treatment in the NOD mouse: effects on diabetes and insulitis suppression and autoantibody levels. Diabetes Res 15 (1990) 95-102
62. European Nicotinamide Diabetes Intervention Trial (ENDIT) group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial if intervention before the onset of type 1 diabetes. Lancet 363 (2004) 925-931
63. Crino A., Schiaffinin R., Manfrini S., et al. A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX). Eur J Endocrinol 150 (2004) 719-724
64. Crino A., Schiaffini R., Ciampalini P., et al. A two year observational study of nicotinamide and intensive insulin therapy in patients with recent onset type 1 diabetes mellitus. J Pediatr Endocrinol Metab 18 (2005) 749-754
65. Pozzilli P., Visalli N., Boccuni M.L., et al. Randomized trial comparing nicotinamide and nicotinamide plus cyclosporin in recent onset insulin-dependent diabetes (IMDIAB 1). The IMDIAB Study Group. Diabet Med 11 (1994) 98-104
66. Stiller C.R., Dupre J., Gent M., et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 223 4643 (1984) 1362-1367
67. Stiller C.R., Dupre J., Gent M., et al. Effects of cyclosporine in recent-onset juvenile type 1 diabetes: impact of age and duration of disease. J Pediatr 111 6 Pt 2 (1987) 1069-1072
68. Silverstein J., Maclaren N., Riley W., et al. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 319 10 (1988) 599-604
69. Bougneres P.F., Carel J.C., Castano L., et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 318 11 (1988) 663-670
70. Bougnères P.F., Landais P., Boisson C., et al. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 39 10 (1990) 1264-1272
71. Parving H.H., Tarnow L., Nielsen F.S., et al. Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. Diabetes Care 22 3 (1999) 478-483
72. Cosimi A.B., Burton R.C., Colvin R.B., et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 32 (1981) 535-539
73. Friend P.J., Hale G., Chatenoud L., et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 32 (1981) 535-539
74. Smith J.A., Tso J.Y., Clark M.R., et al. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J Exp Med 185 (1997) 1413-1422
75. Chatenoud L., Baudrihaye M.F., Kreis H., et al. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur J Immunol 12 11 (1982) 979-982
76. Chatenoud L., Thervet E., Primo J., et al. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A 91 (1994) 123-127
77. Chatenoud L., Primo J., and Bach J.F. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 158 (1997) 2947-2954
78. Herold K.C., Burton J.B., Francois, et al. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1 (Ala-Ala). J Clin Invest 111 (2003) 409-418
79. Belghith M., Bluestone J.A., Barriot S., et al. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 9 9 (2003) 1202-1208
80. Bisikirska B., Colgan J., and Luban J. TCR stimulation with modified anti-CD3 mAb expands CD8 T cell population and induces CD8CD25 Tregs. J Clin Invest 115 10 (2005) 2904-2913
81. You S., Leforban B., Garcia C., et al. Adaptive TCG-β-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A 104 (2007) 6335-6340
82. Herold K.C., Hagopian W., Auger J.A., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346 22 (2002) 1692-1698
83. Herold K.C., Gitelman S.E., Masharani U., et al. A single course of anti-CD3 monoclonal antibody hOKT3{gamma}1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54 6 (2005) 1763-1769
84. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352 25 (2005) 2598-2608
85. Ablamunits V., Sherry N.A., Kushner J.A., et al. Autoimmunity and Beta cell regeneration in mouse and human type 1 diabetes: the peace is not enough. Ann N Y Acad Sci 1103 (2007) 19-32
86. Von Herrath M., Sanda S., and Herold K. Type 1 diabetes as a relapsing-remitting disease?. Nat Rev Immunol 7 (2007) 988-994
87. Chatenoud L., and Bluestone J.A. CD3-specfic antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 7 (2007) 622-632
88. Bresson D., Togher L., Rodrigo E., et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 116 (2006) 1371-1381
89. Bour-Jordan H., and Bluestone J.A. B cell depletion: a novel therapy for autoimmune diabetes?. J Clin Invest 117 12 (2007) 3642-3645
90. Bonner-Weir S. Perspective: postnatal pancreatic β cell growth. Endocrinology 141 (2000) 1926-9
91. Tsai E.B., Sherry N.A., Palmer J.P., et al. The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia 49 (2006) 261-270
92. Sherry N.A., Kushner J.A., Glandt M., et al. Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes. Diabetes 55 (2006) 3238-3245
93. Chase H.P., MacKenzie T.A., Burdick J., et al. Redefining the clinical remission period in children with type 1 diabetes. Pediatr Diabetes 5 1 (2004) 16-19
94. Palmer J.P., Fleming G.A., Greenbaum C.J., et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 53 1 (2004) 250-264
95. Sherry N.A., Tsai E.B., and Herold K.C. Natural history of β-cell function in type 1 diabetes. Diabetes 54 (2005) S32-S39
96. Xu G., Stoffers D.A., and Habener J.F. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48 12 (1999) 2270-2276
97. Zhang J., Tokui Y., Yamagata K., et al. Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays the onset of autoimmune type 1 diabetes. Diabetologia 50 (2007) 1900-1909
98. Service G.J., Thompson G.B., Service F.J., et al. Hyperinsulinemic hypoglycaemia with nesidoblastosis after gastric-bypass surgery. N Engl J Med 353 (2005) 249-254
99. Cummings D.E., Overduin J., Foster-Schubert K.E., et al. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 89 (2004) 2608-2615
100. Amori R.E., Lau J., and Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298 2 (2007) 194-206
101. Ogawa N., List J.F., Habener J.F., et al. Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes 53 7 (2004) 1700-1705
102. Sherry N.A., Chen W., Kushner J.A., et al. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of β-cells. Endocrionology 148 (2007) 5138-5144
103. Sherr J., Sosenko J., Skyler J.S., et al. Prevention of type 1 diabetes: the time has come. Nat Clin Pract Endocrinol Metab 4 (2008) 334-343
104. Skyler J.S. Prediction and prevention of type 1 diabetes: progress, problems, and prospects. Clin Pharmacol Ther 81 (2007) 768-771
105. Bresson D., and Von Herrath M. Moving to efficient therapies in type 1 diabetes: to combine or not to combine. Autoimmun Rev 6 (2007) 315-322
106. Cobbold S.P., Adams E., Graca L., et al. Immune privilege induced by regulatory T cells in transplantation tolerance. Immun 213 (2006) 239-255
107. Nir T., Melton D.A., and Dor Y. Recovery from diabetes in mice β cell regeneration. J Clin Invest 117 (2007) 2553-2561
108. Bluestone J.A., Thomson A.W., Shevach E.M., et al. What does the future hold for cell-based tolergenic therapy?. Nat Rev Immunol 7 (2007) 650-654
109. Seyfert-Margolis V., Gisler T.D., Asare A.L., et al. Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes. Diabetes 55 (2006) 2588-2594
110. Bennett L., Palucka A.K., Arce E., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 197 6 (2003) 711-723